Mackenzie Financial Corp Sells 7,137 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Mackenzie Financial Corp decreased its position in United Therapeutics Co. (NASDAQ:UTHR) by 31.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,263 shares of the biotechnology company’s stock after selling 7,137 shares during the quarter. Mackenzie Financial Corp’s holdings in United Therapeutics were worth $4,862,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. ClariVest Asset Management LLC lifted its position in United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 42 shares during the last quarter. V Square Quantitative Management LLC bought a new stake in United Therapeutics in the second quarter valued at approximately $30,000. Innealta Capital LLC bought a new stake in United Therapeutics in the second quarter valued at approximately $33,000. Rise Advisors LLC bought a new stake in United Therapeutics in the first quarter valued at approximately $32,000. Finally, Benjamin F. Edwards & Company Inc. lifted its position in United Therapeutics by 63.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 117 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on UTHR shares. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 2nd. Oppenheimer boosted their target price on United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a research note on Wednesday, August 28th. TD Cowen boosted their target price on United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. LADENBURG THALM/SH SH cut United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Morgan Stanley cut United Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their target price for the company from $310.00 to $321.00 in a research note on Thursday, July 11th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $357.17.

United Therapeutics Price Performance

Shares of UTHR stock opened at $357.83 on Wednesday. The stock has a market cap of $15.87 billion, a price-to-earnings ratio of 16.92, a PEG ratio of 1.30 and a beta of 0.57. The business’s fifty day moving average is $343.01 and its 200 day moving average is $297.78. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $366.08. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). The firm had revenue of $714.90 million during the quarter, compared to analysts’ expectations of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. United Therapeutics’s revenue for the quarter was up 19.8% on a year-over-year basis. During the same period in the previous year, the company earned $5.24 earnings per share. Research analysts expect that United Therapeutics Co. will post 24.71 EPS for the current fiscal year.

Insider Transactions at United Therapeutics

In other news, CFO James Edgemond sold 7,792 shares of the stock in a transaction on Monday, September 30th. The stock was sold at an average price of $358.62, for a total value of $2,794,367.04. Following the sale, the chief financial officer now directly owns 4,802 shares of the company’s stock, valued at $1,722,093.24. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CFO James Edgemond sold 7,792 shares of the stock in a transaction on Monday, September 30th. The stock was sold at an average price of $358.62, for a total value of $2,794,367.04. Following the sale, the chief financial officer now directly owns 4,802 shares of the company’s stock, valued at $1,722,093.24. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 269 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $348.41, for a total value of $93,722.29. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at $45,293.30. The disclosure for this sale can be found here. Over the last three months, insiders have sold 111,844 shares of company stock valued at $37,455,246. Insiders own 12.50% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.